Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Skyline Capital Management launching UCITS version of global long/short equity fund

Monday, June 27, 2011

Geoff Bamber
Opalesque Industry Update London-based, Skyline Capital Management is launching a UCITs version of their global long/short equities strategy that focuses on emerging markets opportunities. The Skyline UCITS Fund will be available on August 1, 2011, through the MontLake UCITS Platform and according to a press release issued by MontLake has over $25m in committed launch allocations.

A global, long/short equity specialist, Skyline Capital launched in 2010, by Geoff Bamber, formerly of Nevsky Capital and Matterhorn Investment. Earlier this month, Bamber, who is CIO and Vernon West (CEO) announced a seed investment into the firms global fund, propelling it past the $10m mark.

We are delighted to be launching our UCITS fund on the MontLake platform. Our focus on investing in liquid emerging markets companies is a natural fit for the UCITS format, and we have invested significantly in our infrastructure to maximize our operational strength in advance of launch, said West.

For London based (but Malta regulated) ML Capital Asset Management, which launched its MontLake UCITS platform with David Yarrow's UCITS version of the Pegasus Fund in October 2010, Skyline marks the fourth fund the platform has launched, and it is also the highest asset launch to date. The firm says that the typical time to launch a UCITS fund on the turnkey platform is 10 weeks or less and MontLake intends to meet its goal of ending 2011 with a diversified portfolio of eight funds available to investors.

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for